BridgeBio Pharma Touts Attruby Uptake, Bayer's Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf [Yahoo! Finance]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
treatment-naïve share north of 25% and net pricing described as very stable with gross-to-net in the 30–40% range. Bayer's European rollout of acoramidis (Beyonttra) began in Germany with reported treatment-naïve share 50%, and BridgeBio's royalties start at 30% and can rise into the mid-to-high-30% range, representing a potentially meaningful revenue stream. Key pipeline timelines: BridgeBio plans an in-house TTR “depleter” to enter the clinic by late next year/early 2028, and expects to file a U.S. NDA for infigratinib in H2 with a possible U.S. launch in H1 next year, while operating spend could rise toward ~$300M by late 2026–2027 as launches scale. Interested in BridgeBio Pharma, Inc.? Here are five stocks we like better. BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope BridgeBio Pharma (NASDAQ:BBIO) highlighted accelerating U.S. uptake for its transthyretin (TTR) stabilizer Attruby and laid out key timelines for upcoming launches and pipeline programs d
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio Pharma (BBIO) had its "outperform" rating reaffirmed by Leerink Partners.MarketBeat
- BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 [Yahoo! Finance]Yahoo! Finance
- BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9GlobeNewswire
- BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade [Yahoo! Finance]Yahoo! Finance
- BridgeBio Pharma (BBIO) had its "overweight" rating reaffirmed by Barclays PLC.MarketBeat
BBIO
Earnings
- 2/24/26 - Miss
BBIO
Sec Filings
- 3/13/26 - Form 144
- 3/12/26 - Form 4
- 3/10/26 - Form 144
- BBIO's page on the SEC website